Evotec shares rise 2.05% intraday after Kazia Therapeutics announced new findings from a collaborative research program.

Evotec SE rose 2.05% in intraday trading, with Kazia Therapeutics Limited announcing new findings from a collaborative research program led by Professor Sudha Rao at QIMR Berghofer. The study evaluated the effect of paxalisib, Kazia's investigational PI3K-mTOR inhibitor, on metastatic burden in Stage IV HER2-positive metastatic breast cancer patients. This news is positive for Evotec SE as it highlights the potential of their research and collaboration in developing new therapeutic options for a challenging clinical area.